PPAR-y, a major target for the antidiabetic thiazolidinediones (TZDs), is a transcription factor that occupies a position integrating metabolic and cardiovascular responses. PPAR-y is critical for adipogenesis and mutations in PPAR-y have been shown to cause insulin resistance, diabetes and hypertension. TZDs have recently been shown to alter blood pressure in animals and humans and to modify vascular endothelial and smooth muscle function. Therefore, PPAR-y is likely candidate for mediating the interface between metabolic disease and cardiovascular disease. However, it is unclear if PPAR-y in vascular tissues is critical to in vivo responses and whether TZD effects on vascular function are mediated by PPAR-y. Our goal is to determine the role of PPAR-y in cardiac and vascular cells and to determine its role in mediating the associations of metabolic and cardiovascular diseases. This proposal will answer three critical questions. What is the physiologic function of PPAR-y in the cardiovascular system in otherwise normal animals? What is the role of PPAR-y in pathologic disease models? Finally, what are the mechanisms of PPAR-y and TZD effects (i.e. what TZD effects mediated by PPAR-y and what are the molecular mechanisms?)? To answer these questions, we have produced a novel """"""""whole body"""""""" PPAR-y knockout, cardiomyocyte and endothelial cell-type restricted knockouts and propose smooth muscle cell knockouts. We will use a multidisciplinary approach, focused on these gene knockouts, to determine the physiologic role and mechanisms of action of the cardiovascular PPAR-y. By determining the phenotype of these knockout animals we anticipate defining the role of PPAR-y in cardiovascular tissue. Therefore, we will be able to determine if PPAR-y mediates TZD effects. Based on our preliminary data, we will test the hypothesis that PPAR-y is critical to normal regulation of cardiovascular cell growth, protects cells from diabetic glucolipotoxicity and regulates blood pressure (likely predominately in the endothelial cell)-All in a physiologic important context.. ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL083201-01
Application #
7021909
Study Section
Atherosclerosis and Inflammation of the Cardiovascular System Study Section (AICS)
Program Officer
Rabadan-Diehl, Cristina
Project Start
2006-03-01
Project End
2010-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
1
Fiscal Year
2006
Total Cost
$380,833
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Physiology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Li, Chao; Zhang, Yu Yao; Frieler, Ryan A et al. (2014) Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One 9:e110950
He, Huamei; Tao, Hai; Xiong, Hui et al. (2014) Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor ?-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci 138:468-81
Shen, Zhuxia; Li, Chao; Frieler, Ryan A et al. (2012) Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in mice. Biochem Biophys Res Commun 422:639-42
Frieler, Ryan A; Ramnarayanan, Saiprasad; Mortensen, Richard M (2012) Nuclear receptor control of opposing macrophage phenotypes in cardiovascular disease. Front Biosci (Landmark Ed) 17:1917-30
Frieler, Ryan A; Meng, He; Duan, Sheng Zhong et al. (2011) Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42:179-85
Usher, Michael G; Duan, Sheng Zhong; Ivaschenko, Christine Y et al. (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350-64
Duan, S Z; Usher, M G; Foley 4th, E L et al. (2010) Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice. Diabetologia 53:1493-505
Duan, Sheng Zhong; Usher, Michael G; Mortensen, Richard M (2009) PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 18:128-33
Duan, Sheng Zhong; Usher, Michael G; Mortensen, Richard M (2008) Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102:283-94
Duan, Sheng Zhong; Christe, Michael; Milstone, David S et al. (2007) Go but not Gi2 or Gi3 is required for muscarinic regulation of heart rate and heart rate variability in mice. Biochem Biophys Res Commun 357:139-43

Showing the most recent 10 out of 13 publications